Semaglutide for Recovery
The GLP-1 pioneer for sustainable weight loss and cardiovascular health.
Why Semaglutide for recovery?
Extensively studied in the STEP clinical trials, Semaglutide (sold as Wegovy® and Ozempic®) has demonstrated up to 15% weight loss in adults. Ongoing research (2024-2026) highlights its potent cardiovascular benefits even in non-diabetic populations.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. Semaglutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Significant weight loss
- Improved blood sugar control
- Reduces heart attack/stroke risk
- Strong appetite suppression
Reference dosing by bodyweight
Anchored to the most-cited research dose (25000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 15583–21083 mcg |
| 60–75 kg / 132–165 lb | 19125–25875 mcg |
| 75–90 kg / 165–198 lb | 23375–31625 mcg |
| 90–105 kg / 198–231 lb | 27625–37375 mcg |
| >105 kg / >231 lb | 31875–43125 mcg |
Side effects to weigh against recovery benefit
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.